Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesImmuCell Corporation

ImmuCell Corporation

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
10.22 USD 0.00(0%)
Last update at 2026-11-09T21:00:00Z
VOLUME
6264
Market Cap
87.01M
P/E
136.86

Momentum Score

…

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
9.94
Low
10.38
High
52 Week Price Range
4.52
Low
12.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

ImmuCell Corporation is a U.S. animal‑health company that produces treatments for dairy and beef cattle focused on mastitis prevention and supporting calf immunity. Long-term growth drivers include steady demand for livestock health products, wider adoption of preventive therapies, and product or geographic expansion that could support recurring sales.

Principal risks are exposure to dairy/beef industry cycles, competition from larger animal-health firms, regulatory uncertainty, and limited scale that can cause volatile earnings.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
10.22
Dividend Yield
-
Revenue TTM
30.68M
Revenue Per Share
3.39
Gross Profit TTM
12.37M
Debt / Equity
0.49
ROE
2.57%
Net Debt
9.39M
ROCE
-1.53%
Diluted EPS TTM
0.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1.03M -2.15M -5.77M -2.49M -0.07M
Net income -1.04M -2.16M -5.77M -2.49M -0.08M
Selling general administrative 3.20M 2.22M 2.13M 2.26M 1.73M
Selling and marketing expenses 3.55M 3.47M 3.09M 5.45M 4.23M
Gross profit 11.45M 7.94M 4.40M 7.65M 8.66M
Reconciled depreciation 2.73M 2.69M 2.65M 2.49M 2.46M
Ebit -0.59M -1.62M -5.22M -4.79M -2.20M
Ebitda 2.14M 1.07M -2.50M -2.30M 0.26M
Depreciation and amortization 2.73M 2.69M 2.72M 2.49M 2.46M
Operating income 1.65M -1.64M -5.75M -2.30M -2.20M
Other operating expenses 25.99M 28.13M 23.22M 20.87M 18.99M
Interest expense 0.44M 0.57M 0.45M 0.34M 0.31M
Tax provision 0.01M 0.01M 0.00M 0.01M 0.01M
Interest income 0.16M 0.08M 0.14M 0.15M 0.02M
Net interest income -0.33M -0.49M -0.27M -0.20M -0.30M
Income tax expense 0.01M 0.01M 0.00M 0.01M 0.01M
Total revenue 27.64M 26.49M 17.47M 18.57M 19.24M
Total operating expenses 9.80M 9.58M 10.14M 9.95M 8.40M
Cost of revenue 16.20M 18.55M 13.08M 10.92M 10.59M
Total other income expense net -2.68M -0.51M -0.02M -0.19M 2.14M
Net income from continuing ops -1.04M -2.16M -6.30M -2.49M -0.08M
Net income applicable to common shares - - - -2493.80M -0.08M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 42.53M 45.10M 43.81M 44.86M 44.47M
Intangible assets - 0.02M 0.04M 0.06M 0.08M
Other current assets 0.45M 0.36M 0.45M 0.41M 0.27M
Total liab 15.48M 17.58M 18.82M 14.48M 11.89M
Total stockholder equity 27.06M 27.52M 24.99M 30.38M 32.58M
Other current liab 1.49M 1.54M 1.23M 1.21M 0.87M
Common stock 0.91M 0.90M 0.78M 0.78M 0.78M
Capital stock 0.91M 0.90M - 0.78M 0.78M
Retained earnings -15.20M -14.16M -12.01M -6.23M -3.74M
Good will 0.10M 0.10M 0.10M 0.10M 0.10M
Other assets 29.46M - 0.00M 0.00M 0.00M
Cash 3.81M 3.76M 0.98M 5.79M 10.19M
Total current liabilities 3.98M 4.41M 4.20M 3.07M 2.53M
Current deferred revenue - - 0.00M - -
Net debt 9.39M 11.34M 15.71M 6.69M 0.09M
Short term debt 1.70M 1.93M 2.07M 1.07M 0.92M
Short long term debt 1.61M 1.50M - 1.04M 0.81M
Short long term debt total 13.19M 15.10M 16.69M 12.48M 10.27M
Other stockholder equity 41.35M 40.78M 36.22M 35.83M 35.53M
Property plant equipment - - - 30636.40M 28.00M
Total current assets 16.94M 15.04M 11.47M 13.99M 16.26M
Net tangible assets - - - 30227.18M 32.29M
Short term investments - - - - -0.00M
Net receivables 3.42M 3.81M 2.23M 1.80M 2.72M
Long term debt 7.49M 9.04M - 9.19M 8.33M
Inventory 9.27M 7.11M 7.81M 6.04M 3.09M
Accounts payable 0.80M 0.94M 0.89M 0.79M 0.75M
Accumulated other comprehensive income - 26.41M 0.00M - -
Non currrent assets other 25.49M 0.03M 0.06M 0.08M 0.03M
Non current assets total 25.59M 30.06M 32.34M 30.87M 28.20M
Capital lease obligations 4.10M 4.56M - 2.25M 1.14M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.46M -3.41M -3.96M -1.60M
Change to liabilities - - - 341.61M 0.25M
Total cashflows from investing activities -1.21M -0.46M -1.89M -3964.27M -1.60M
Net borrowings -1.48M -1.47M 1.81M 1102.88M -0.37M
Total cash from financing activities -1.21M 2.88M 1.75M 1.11M 3.88M
Change to operating activities - - - -161.37M 0.03M
Net income -1.04M -2.16M -5.77M -2.49M -0.08M
Change in cash 0.05M 2.78M -4.81M -4.39M 3.24M
Begin period cash flow 3.76M 0.98M 5.79M 10.19M 6.95M
End period cash flow 3.81M 3.76M 0.98M 5.79M 10.19M
Total cash from operating activities 2.48M 0.36M -4.67M -1.54M 0.95M
Issuance of capital stock 0.35M 4.65M 0.00M 0.00M 4.23M
Depreciation 2.73M 2.69M 2.72M 2.49M 2.46M
Other cashflows from investing activities 0.04M 0.00M 0.00M - -
Change to inventory -2.15M 0.70M -1.77M -2.95M -1.00M
Change to account receivables 0.35M -1.59M -0.43M 0.94M -0.90M
Other cashflows from financing activities -0.08M -0.01M -0.08M -28.66M 0.41M
Change to netincome - - - 287.39M 0.19M
Capital expenditures 1.25M 0.47M 1.89M 3.98M 2.61M
Change in working capital -2.05M -0.41M -2.11M -1.83M -1.62M
Stock based compensation 0.30M 0.33M 0.37M 0.27M 0.14M
Other non cash items 2.54M -0.09M 0.13M 0.03M 0.02M
Free cash flow 1.22M -0.11M -6.57M -5.52M -1.65M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ICCC
ImmuCell Corporation		 -
-%		 10.22 136.86 - 2.84 2.81 2.99 25.25
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

ImmuCell Corporation

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

56 Evergreen Drive, Portland, ME, United States, 04103

207 878 2770

https://immucell.com

73

Name Title Year Born
Mr. Michael F. Brigham Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director 1961
Ms. Bobbi Jo Brockmann VP of Sales & Marketing and Director 1977
Ms. Elizabeth L. Williams VP of Manufacturing Operations 1956
Elizabeth S. Toothaker Director of Fin. & Admin. NA
Mr. A. Gustavo Scaffa Sr. Director of Quality NA
John W. Zinckgraf Director of Product Devel. NA
Mr. Michael F. Brigham President, CEO, Principal Financial Officer, Treasurer, Secretary & Director 1961
Elizabeth S. Toothaker Director of Finance & Administration and Controller NA
Mr. A. Gustavo Scaffa Senior Director of Quality NA
John W. Zinckgraf Director of Product Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…